Breaking News Instant updates and real-time market news.

ATRA

Atara Biotherapeutics

$18.90

0.45 (2.44%)

, MRK

Merck

$62.55

-0.09 (-0.14%)

08:07
04/21/17
04/21
08:07
04/21/17
08:07

Atara Biotherapeutics announces collaboration with Merck

Atara Biotherapeutics (ATRA) announced that it has entered into a clinical trial collaboration agreement with Merck (MRK), to evaluate Atara Bio's allogeneic Epstein-Barr virus, or EBV,-specific cytotoxic T lymphocytes, or ATA129, in combination with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with platinum resistant or recurrent EBV-associated NPC. The Phase 1/2 trial will evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination and is planned for initiation in 2018.

ATRA

Atara Biotherapeutics

$18.90

0.45 (2.44%)

MRK

Merck

$62.55

-0.09 (-0.14%)

  • 22

    Apr

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

ATRA Atara Biotherapeutics
$18.90

0.45 (2.44%)

10/24/16
JEFF
10/24/16
INITIATION
Target $23
JEFF
Buy
Atara Biotherapeutics assumed with a Buy at Jefferies
Jefferies analyst Gena Wang assumed coverage of Atara Biotherapeutics with a Buy rating and $23 price target. The company's off-the-shelf cytotoxic T-lymphocytes technology could offer differentiated advantages, Wang contends.
11/21/16
WBLR
11/21/16
NO CHANGE
WBLR
Outperform
William Blair views Atara as 'overlooked and misunderstood'
William Blair analyst John Sonnier feels Atara Biotherapeutics, following last year's failure of a molecularly targeted pipeline candidate in a Phase II protein-energy wasting trial, has been "overlooked and misunderstood" by investors. Since the failure, the company has made "important advances with a differentiated T-cell platform," with plans to initiate two Phase III clinical trials by the end of this year, Sonnier tells investors in a research note. He believes Atara shares are fundamentally undervalued and reiterates an Outperform rating on the shares.
12/14/16
SBSH
12/14/16
NO CHANGE
Target $8
SBSH
Sell
Citi says Atara Biotherapeutics sell thesis is working
Citi analyst Yigal Nochomovitz believes his thesis on Atara Biotherapeutics is working after the company this week said it will not be able to start Phase 3 trials by the end of 2016. The analyst keeps a Sell rating on the shares with an $8 price target.
03/15/17
SBSH
03/15/17
NO CHANGE
Target $10
SBSH
Sell
Citi sees 50% downside risk in shares of Atara
Citi analyst Yigal Nochomovitz reiterates a Sell rating and $10 price target on shares of Atara Biotherapeutics following the stock's 40% rally this morning. The price target reflects 50% downside from current levels, the analyst points out. The stock rally came in the absence of new clinical data and with minimal updates on the pipeline, Nochomovitz tells investors in a research note. He continues to believe Atara's markets are relatively niche.
MRK Merck
$62.55

-0.09 (-0.14%)

04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.
04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/23/17
04/23
04:55
04/23/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

AAPL

Apple

$142.27

-0.17 (-0.12%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

13:57
04/22/17
04/22
13:57
04/22/17
13:57
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$142.27

-0.17 (-0.12%)

FB

Facebook

$143.68

-0.12 (-0.08%)

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

AKS

AK Steel

$6.72

-0.1 (-1.47%)

X

U.S. Steel

$30.42

-0.09 (-0.29%)

NUE

Nucor

$60.00

-0.35 (-0.58%)

CYH

Community Health

$8.24

-0.11 (-1.32%)

HCA

HCA Holdings

$83.55

-0.57 (-0.68%)

LPNT

LifePoint

$60.85

-0.7 (-1.14%)

THC

Tenet

$15.35

0.36 (2.40%)

UHS

Universal Health

$118.84

-0.29 (-0.24%)

HUM

Humana

$213.67

-0.57 (-0.27%)

BAC

Bank of America

$22.71

-0.36 (-1.56%)

C

Citi

$57.72

-0.69 (-1.18%)

GS

Goldman Sachs

$216.86

-1.2 (-0.55%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

USB

U.S. Bancorp

$50.51

-0.17 (-0.34%)

WFC

Wells Fargo

$53.00

-0.5 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 16

    May

  • 16

    May

  • 19

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 25

    May

  • 06

    Jun

  • 06

    Jun

  • 13

    Jun

  • 13

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

JNS

Janus Capital

$13.15

-0.07 (-0.53%)

13:27
04/22/17
04/22
13:27
04/22/17
13:27
Conference/Events
Janus Capital to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ABT

Abbott

$43.53

-0.45 (-1.02%)

, ABBV

AbbVie

$63.82

0.04 (0.06%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
National Kidney Foundation to hold clinical meeting »

NKF 2017 Spring Clinical…

ABT

Abbott

$43.53

-0.45 (-1.02%)

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

AMGN

Amgen

$160.41

-1.63 (-1.01%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

GSK

GlaxoSmithKline

$40.78

0.07 (0.17%)

HZNP

Horizon Pharma

$14.99

-0.25 (-1.64%)

MNK

Mallinckrodt

$43.52

-1.41 (-3.14%)

MRK

Merck

$61.89

-0.66 (-1.06%)

AUPH

Aurinia Pharmaceuticals

$7.11

0.11 (1.57%)

NXTM

NxStage Medical

$27.90

-0.19 (-0.68%)

PLX

Protalix

$1.02

0.02 (2.00%)

RTRX

Retrophin

$18.47

-0.37 (-1.96%)

SNY

Sanofi

$44.09

-0.7 (-1.56%)

SHPG

Shire

$171.94

0.08 (0.05%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 27

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

  • 26

    Jun

  • 19

    Jul

  • 14

    Aug

  • 23

    Oct

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 22

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

RGEN

Repligen

$35.06

-0.78 (-2.18%)

19:19
04/21/17
04/21
19:19
04/21/17
19:19
Initiation
Repligen initiated at First Analysis »

Repligen initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 30

    May

  • 06

    Jun

TWTR

Twitter

$14.63

-0.02 (-0.14%)

18:07
04/21/17
04/21
18:07
04/21/17
18:07
Periodicals
Homeland Security investigates potential abuse in Twitter case, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$843.19

1.54 (0.18%)

, GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

17:46
04/21/17
04/21
17:46
04/21/17
17:46
Periodicals
Waymo:Uber misled court on Levandowski using LIDAR secrets, Bloomberg says »

According to Bloomberg,…

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 22

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
CareDx receives expected letter from Nasdaq »

CareDx announced that, as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$44.45

-0.2 (-0.45%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
Greenbrier CEO intends to sell one-half of his position in company stock »

The CEO of The Greenbrier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx backs FY17 revenue view $45M-$50M, consensus $47.62M »

Revenue view excludes any…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx reports Q4 adjusted EPS (13c), consensus (18c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMMA

Alliance MMA

$1.69

-0.05 (-2.87%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Hot Stocks
Alliance MMA announces shareholder filed lawsuit against the company »

Alliance MMA announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:30
04/21/17
04/21
17:30
04/21/17
17:30
Hot Stocks
CareDx names Michael Bell CFO »

CareDx announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

, XOMA

XOMA

$7.73

0.26 (3.48%)

17:22
04/21/17
04/21
17:22
04/21/17
17:22
Hot Stocks
Novo Nordisk terminates exclusive license agreement with XOMA »

On April 20, XOMA (XOMA)…

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

XOMA

XOMA

$7.73

0.26 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 07

    May

  • 18

    May

  • 06

    Jun

HH

Hooper Holmes

$0.72

-0.1973 (-21.44%)

17:21
04/21/17
04/21
17:21
04/21/17
17:21
Hot Stocks
Breaking Hot Stocks news story on Hooper Holmes »

John Pappajohn reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBMS

First Bancshares

$28.00

0.15 (0.54%)

17:14
04/21/17
04/21
17:14
04/21/17
17:14
Earnings
First Bancshares reports Q1 EPS 12 c with items, consensus 35c »

Reports Q1 provision for …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRWI

DragonWave

$1.23

-0.025 (-2.00%)

17:04
04/21/17
04/21
17:04
04/21/17
17:04
Hot Stocks
DragonWave did not regain compliance with Nasdaq listing standards »

DragonWave announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:02
04/21/17
04/21
17:02
04/21/17
17:02
Hot Stocks
Sears establishes special committee to market certain real estate properties »

Sears Holdings said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
Sears names Rob Riecker CFO »

Sears announced that Rob…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

UAL

United Continental

$69.56

-0.24 (-0.34%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
UAL: employee incentive opportunity to be tied to 'customer experience' »

United Continental said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Earnings
Sears sees FY17 net income $185M-$285M »

"The retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

16:59
04/21/17
04/21
16:59
04/21/17
16:59
Hot Stocks
Sears raises annualized cost savings target to $1.25B from $1B »

Sears Holdings provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

LTBR

Lightbridge

$1.25

-0.06 (-4.58%)

16:51
04/21/17
04/21
16:51
04/21/17
16:51
Hot Stocks
CEO of Lightbridge Seth Grae reports 5.1% stake in company »

As of March 22, Seth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IONS

Ionis Pharmaceuticals

$44.26

1.35 (3.15%)

16:46
04/21/17
04/21
16:46
04/21/17
16:46
Syndicate
Breaking Syndicate news story on Ionis Pharmaceuticals »

Ionis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.